Related Experiment Video

Updated: Jun 13, 2026

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
06:15

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Published on: October 27, 2014

Patterns of relapse and prognosis after bevacizumab failure in recurrent glioblastoma

Marc C Chamberlain, Andrew B Lassman, Fabio M Iwamoto

    Neurology
    |April 14, 2010
    PubMed
    Abstract

    No abstract available in PubMed .

    More Related Videos

    Glioblastoma Relapse Post-Resection Model for Therapeutic Hydrogel Investigations
    04:46

    Glioblastoma Relapse Post-Resection Model for Therapeutic Hydrogel Investigations

    Published on: February 24, 2023

    The Clinical Application of Tumor Treating Fields Therapy in Glioblastoma
    08:00

    The Clinical Application of Tumor Treating Fields Therapy in Glioblastoma

    Published on: April 16, 2019

    Related Experiment Videos

    Last Updated: Jun 13, 2026

    Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
    06:15

    Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

    Published on: October 27, 2014

    Glioblastoma Relapse Post-Resection Model for Therapeutic Hydrogel Investigations
    04:46

    Glioblastoma Relapse Post-Resection Model for Therapeutic Hydrogel Investigations

    Published on: February 24, 2023

    The Clinical Application of Tumor Treating Fields Therapy in Glioblastoma
    08:00

    The Clinical Application of Tumor Treating Fields Therapy in Glioblastoma

    Published on: April 16, 2019

    Related Concept Videos

    Treatment Resistent Cancers02:56

    Treatment Resistent Cancers

    Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
    Treatment Resistant Cancers02:56

    Treatment Resistant Cancers

    Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...

    Articles linked to this work by shared authors, journal, and citation graph.

    Efficacy and safety of tirabrutinib monotherapy for relapsed/refractory primary CNS lymphoma: PROSPECT phase 2 trial.

    Blood·2026

    NeuroRAD-FM: A Distributionally Robust Foundation Model for Precision Neuro-Oncology.

    Research square·2026

    Tocilizumab, atezolizumab, and stereotactic radiotherapy in recurrent glioblastoma: primary analysis of safety and efficacy of a phase 2 trial, NRG Oncology-BN010.

    International journal of radiation oncology, biology, physics·2026

    The evolution of RTOG and NRG Oncology CNS tumors clinical trials.

    Journal of neuro-oncology·2026

    Prognostic and Predictive Effect of Age in Molecularly Defined Lower-Grade Gliomas.

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026

    Eosinophil counts as a prognostic marker in glioblastoma: a retrospective cohort study.

    BMC cancer·2026

    Acute Imbalance Syndrome vs Acute Vestibular Syndrome: Clinical and Topographical Differentiation.

    Neurology·2026

    Effects of Blood Pressure Lowering by Hematoma Location in Acute Intracerebral Hemorrhage.

    Neurology·2026

    Neurology Journal Club: Characteristics and Outcomes of Patients With IDH-Mutant Grade 2 and 3 Gliomas After Deferred or Adjuvant Radiotherapy.

    Neurology·2026

    Relationship Between Braak and Clinical Stage in Autopsy-Confirmed Parkinson Disease: A UK Brain Bank Study.

    Neurology·2026

    Emergency Department Visits for Falls and First-Time Seizure.

    Neurology·2026

    Comparative Effectiveness of Treatments for Relapse Prevention in Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease.

    Neurology·2026
    See all related articles
    JoVE
    x logofacebook logolinkedin logoyoutube logo
    ABOUT JoVE
    OverviewLeadershipBlogJoVE Help Center
    AUTHORS
    Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
    LIBRARIANS
    TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
    RESEARCH
    JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
    EDUCATION
    JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
    Terms & Conditions of Use
    Privacy Policy
    Policies
    Jove
    Visualize
    Contact Us